Kowa, Daiichi to terminate Livalo, Olmetec joint marketing partnership in Japan
Livalo, developed by Kowa, is a cholesterol-lowering agent and Olmetec, developed by Daiichi, is an antihypertensive agent. Both the companies have been jointly marketing the drugs in the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.